Arcus Biosciences, Inc.
RCUSDrugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
6
Next Catalyst
This month
Market Overview
Stock performance and key metrics
8 upcoming, 0 past
Domvanalimab Phase 2 Est. Readout
Primary completion for Domvanalimab trial (NCT04736173) in Non Small Cell Lung Cancer
SourceZimberelimab Phase 3 Results Expected
Primary completion for Zimberelimab trial (NCT05568095) in Advanced Upper Gastrointestinal Tract Adenocarcinoma
lung trial futility results
SourceDomvanalimab Phase 3 Results Expected
Primary completion for Domvanalimab trial (NCT05568095) in Advanced Upper Gastrointestinal Tract Adenocarcinoma
Phase 3 failure in TIGIT asset led to termination of mid-stage study
Source5 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Zimberelimab
Non Small Cell Lung Cancer
Nab-paclitaxel
Metastatic Pancreatic Ductal Adenocarcinoma
Casdatifan
Metastatic Clear Cell Renal Cell Carcinoma
Domvanalimab
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Quemliclustat
Gastrointestinal Tract Malignancies
Etrumadenant
Prostatic Neoplasms, Castration-Resistant
AB680
Metastatic Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Zimberelimab | Phase 3 | Non Small Cell Lung Cancer | - | - |
Nab-paclitaxel | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
Casdatifan | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma | - | - |
Domvanalimab | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | - | - |
Quemliclustat | Phase 3 | Gastrointestinal Tract Malignancies | - | - |
Etrumadenant | Phase 2 | Prostatic Neoplasms, Castration-Resistant | - | - |
AB680 | Phase 2 | Metastatic Colorectal Cancer | - | - |